The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: Involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ji, Dongmei ^a   Zhang, Zhe ^a   Cheng, Lei ^b   Chang, Jinjia ^a   Wang, Shanshan ^a   Zheng, Biqiang ^a   Zheng, Rongliang ^a   Sun, Zuojun ^a   Wang, Chenchen ^a   Zhang, Zhiqing ^c   Liu, Rujiao ^a   Zhang, Xiaowei ^a   Liu, Xin ^a   Wang, Xiaofeng ^a   Li, Jin ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SUZHOU MUNICIPAL HOSPITAL   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 METHYLADENINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BECLIN 1; CHLOROQUINE; CYCLIN D1; EVEROLIMUS; LIGHT CHAIN 3B PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STOMACH CANCER;

ADENINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BUTADIENES; CELL LINE, TUMOR; CHLOROQUINE; CYCLIN D1; DRUG SYNERGISM; FLAVONOIDS; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84897431613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085116     Document Type: Article

References (45)

1. Mezhir JJ, Tang LH, Coit DG (2010) Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 101: 305-314.
2. Cervantes A, Roda D, Tarazona N, Rosello S, Perez-Fidalgo JA (2013) Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 39: 60-67.
3. Smyth EC, Cunningham D (2012) Targeted therapy for gastric cancer. Curr Treat Options Oncol 13: 377-389.
4. Almhanna K, Strosberg J, Malafa M (2011) Targeting AKT protein kinase in gastric cancer. Anticancer Res 31: 4387-4392.
5. Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, et al. (2012) Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 18: 6577-6586.
6. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529.
7. Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ, et al. (2012) Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: A novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol.
8. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412.
9. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
10. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. (Pubitemid 47001784)
11. Pal SK, Reckamp K, Yu H, Figlin RA (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355-1366.
12. Wu P, Hu YZ (2010) PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem 17: 4326-4341.
13. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
14. Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13: 3109-3114. (Pubitemid 46944891)
15. Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, et al. (2012) Rash to the mTOR Inhibitor Everolimus: Systematic Review and Meta-Analysis. Am J Clin Oncol.
16. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, et al. (2009) AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 15: 1277-1287.
17. Wang X, Yue P, Kim YA, Fu H, Khuri FR, et al. (2008) Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 68: 7409-7418.
18. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9: 1956-1967.
19. Zhang XW, Zhang L, Qin W, Yao XH, Zheng LZ, et al. (2010) Oncogenic role of the chromobox protein CBX7 in gastric cancer. J Exp Clin Cancer Res 29: 114.
20. Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, et al. (2010) BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 9: 40.
21. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, et al. (2008) Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10: 287-297. (Pubitemid 351328587)
22. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, et al. (2003) Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 104: 318-327. (Pubitemid 36249814)
23. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
24. Wu C-H, Cao C, Kim JH, Hsu C-H, Wanebo HJ, et al. (2012) Trojan-horse nanotube on-command intracellular drug delivery. Nano Letters 12: 5475-5480.
25. Gozuacik D, Kimchi A (2007) Autophagy and cell death. Curr Top Dev Biol 78: 217-245.
26. Yu L, Alva A, Su H, Dutt P, Freundt E, et al. (2004) Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304: 1500-1502. (Pubitemid 38720930)
27. Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 100: 15077-15082. (Pubitemid 37518019)
28. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, et al. (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 285: 10850-10861.
29. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, et al. (2010) Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9: 2423-2433.
30. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA (2010) Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38: 768-774.
31. Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42. (Pubitemid 46014485)
32. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50.
33. Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C (2009) PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 21: 194-198.
34. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, et al. (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11: 85.
35. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
36. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, et al. (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106: 22299-22304.
37. Liu YQ, Cheng X, Guo LX, Mao C, Chen YJ, et al. (2012) Identification of an Annonaceous Acetogenin Mimetic, AA005, as an AMPK Activator and Autophagy Inducer in Colon Cancer Cells. PLoS One 7: e47049.
38. Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13: 132-141.
39. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, et al. (2012) Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142: 1504-1515 e1503.
40. Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 1016-1023.
41. Crazzolara R, Bradstock KF, Bendall LJ (2009) RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 5: 727-728.
42. Lin CI, Whang EE, Donner DB, Du J, Lorch J, et al. (2010) Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res 8: 1217-1226.
43. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, et al. (2012) MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 11: 154-164.
44. Wang J, Whiteman MW, Lian H, Wang G, Singh A, et al. (2009) A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem 284: 21412-21424.
45. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.